[Update on the management of hepatic encephalopathy].
García Martínez
R
R
Servicio Medicina Interna-Hepatología, Hospital Vall d'Hebron, Departamento de Medicina, Universitat Autònoma de Barcelona.
Córdoba Cardona
J
J
D000368:Aged; D000641:Ammonia / Q000037:antagonists & inhibitors / Q000378:metabolism; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000931:Antidotes / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003956:Dialysis; D005442:Flumazenil / Q000627:therapeutic use; D018757:GABA Modulators / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000175:diagnosis / Q000178:diet therapy / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D016031:Liver Transplantation; D015201:Meta-Analysis as Topic; D009355:Neomycin / Q000008:administration & dosage / Q000627:therapeutic use; D011500:Protein Synthesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012294:Rifamycins / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors
D000900:Anti-Bacterial Agents; D000931:Antidotes; D018757:GABA Modulators; D011500:Protein Synthesis Inhibitors; D012294:Rifamycins; D005442:Flumazenil; D000641:Ammonia; D009355:Neomycin